First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Phase 3
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Registration Number
- NCT02883543
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Brief Summary
Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent radiotherapy, or icotinib monotherapy.
- Detailed Description
Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent radiotherapy, or icotinib monotherapy. The primary endpoint is progression-free survival, and the incidence of radiation-induced lung injury.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 330
Inclusion Criteria
- Aged 18 to 75 years
- Pathologically documented NSCLC
- Unresectable stage III or oligometastasis (less than three metastasis lesions, brain metastasis is not permitted) stage IV confirmed by CT and/or MRI
- Positive EGFR mutation confirmed by ARMS
- At least 3-month life expectancy
- KPS ≥ 70
- Adequate hematological values: hemoglobin ≥ 100 g/L, absolute neutrophils count ≥ 1.5 x 109/L, platelets count ≥ 100 x 109/L
- Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT ≤ 1.5 x ULN
- Written informed consent before patient registration and any protocol-related procedures
Exclusion Criteria
- Previous radiotherapy
- Received other investigational systemic drugs within 4 weeks prior to study entry
- Severe or uncontrolled systemic disease
- Active autoimmune disease, or a documented history of autoimmune/acquired immune disease, or a history of organ transplant
- Pregnant or lactating, women of childbearing potential, unless using effective contraception as determined by the investigator
- Any other serious underlying medical (e.g. active uncontrolled infection, active gastric ulcer, uncontrolled seizures), psychological and other condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description icotinib plus radiotherapy Radiotherapy Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy. chemotherapy plus radiotherapy Chemotherapy Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy. chemotherapy plus radiotherapy Radiotherapy Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy. icotinib plus radiotherapy icotinib Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy. icotinib icotinib Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib monotherapy.
- Primary Outcome Measures
Name Time Method Progression-free survival 2 years Incidence of radiation injure of the lungs 2 years Measured according to NCI CTCAE v4.0
- Secondary Outcome Measures
Name Time Method Overall survival 5 years Quality of life 2 years Measured by FACT-L
Tumor response after icotinib induction 8 weeks